Finance

Lists
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$32.68
+1.84%
(+0.59) 1D
Sep 11, 9:47:40 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMLX...
Open
$32.09
High
$33.00
Low
$32.09
Mkt. cap
4.10B
Avg. vol.
3.21M
Volume
19.40K
52-wk high
$41.14
52-wk low
$10.83
EPS
-$1.43
Beta
-0.13
Shares outstanding
125.51M
No. of employees
136
Open
$32.09
High
$33.00
Low
$32.09
Mkt. cap
4.10B
Avg. vol.
3.21M
Volume
19.40K
52-wk high
$41.14
52-wk low
$10.83
EPS
-$1.43
Beta
-0.13
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc
CEO-
Employees136
Founded2013
Headquarters-
SectorPharmaceutical industry
Websiteamylyx.com
Analyst ratings
Based on 10 analysts giving stock ratings to AMLX in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for AMLX in the last 3 months.
Highest
Current $32.68
$57.00 (+74.42%)
Average
$43.00 (+31.58%)
Lowest
$23.00 (-29.62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Seamus Fernandez
Guggenheim
Buy
Reiterated
$57.00
+74.4%
08/26/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$44.00
+34.6%
08/22/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/18/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$39.00
+19.3%
08/18/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
$52.00
+59.1%
08/18/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$55.00
+68.3%
08/20/2026
James Condulis
Stifel Nicolaus
Buy
Reiterated
-
-
08/18/2026
Geoff Meacham
Citi
Buy
Maintained
$32.00
-2.1%
08/19/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$42.00
+28.5%
08/19/2026
Dina Ramadane
Bank of America Securities
Buy
Reiterated
$30.00
-8.2%
08/07/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$34.00
+4%
07/01/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$23.00
-29.6%
06/18/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.39 / -$0.34
-14.45%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
19.86M
21.21M
27.61M
23.77M
Cost of revenue
19.86M
21.21M
27.61M
23.77M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.17M
15.39M
16.17M
21.92M
Operating expense
16.17M
15.39M
16.17M
21.92M
Total operating expenses
36.03M
36.60M
43.78M
45.69M
Operating income
-36.03M
-36.60M
-43.78M
-45.69M
Other non operating income
-
-6.23M
-
-
EBT including unusual items
-34.39M
-32.95M
-41.28M
-43.42M
EBT excluding unusual items
-34.39M
-38.48M
-41.28M
-43.42M
Income tax expense
-
46.00K
-
-
Effective tax rate
-
-0.14%
-
-
Other operating expenses
-
-
-
-
Net income
-34.39M
-33.00M
-41.28M
-43.42M
Net profit margin
-
-
-
-
Earnings per share
-0.37
-0.30
-0.37
-0.39
Interest and investment income
1.82M
3.29M
2.57M
2.32M
Interest expense
-
-
-
-
Net interest expenses
1.82M
3.29M
2.57M
2.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-35.91M
-36.50M
-43.68M
-45.65M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps